Address: Alameda Araguaia, 3833 – Tambore Barueri – São Paulo – Brazil ,Cep: 06455-000
Tel: (+55 11) 4195-6613
Web: http://www.meizler.com.br/
Founded in 1990 with the objective of promoting the development of health in Brazil, Meizler Biopharma, 100% national company, specializes in licensing and acquisition of new drugs and existing partnerships with the world’s leading pharmaceutical / biotech and device doctors.
Aimed at public and private institutions, hospitals and clinics, Meizler Biopharma has full-service warehousing and distribution, dynamically structured to meet increasing government demand for high technology products and affordable prices.
The Wellness division is present in the fastest growing market in Brazil and worldwide, the market for health and beauty. This Business Unit devotes all its energy to developing a marketing strategy and tactics and, together with its international partners, creating a wide and innovative range of products with high added value, backed by the latest technology to meet a discriminating public.
Chronic diseases (diabetes, hemophilia, Wilson’s disease, tuberculosis), Cancer, Transplants, Fertility treatments and Hormone replacement, Biotechnology, Oncology, Blood Products, Immunosuppressants.
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Many international CROs entered Brazil in the past few years, whereas Quintiles made its first move in Brazil in 1996. What was the strategic decision behind entering Brazil at that…
PGS is a member of ABRACRO, but is in a unique position as both a CRO and a service provider to CROs and pharmaceutical companies. Can you elaborate on the…
The government recently released the ‘BrasilMaior’ plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
The government recently released the BrasilMaior plan, whose slogan is “Innovate to compete. Compete to grow.” How would you recommend the government innovate, compete, and grow in the pharmaceutical industry…
We met recently with Minister Pimentel when he launched his BrasilMaior plan, whose slogan was “Innovate to Compete. Compete to Grow.” If you had to make a recommendation to increase…
When we last interviewed you in 2007, you said, “The generics business is a very exciting one,” but you “regret[ted] that the Government is not doing enough work to promote…
As I was doing research on your company, GC-2, I was unable to find a lot of information since it is a rather new company. Could you bring me up…
In a past interview, you said that Ipsen is different than the “Big Pharmas” who have entered Brazil by acquisition. You’ve taken a different tack since arriving as one of…
There is little publicly available information on your personal history and the founding of Meizler. Can you share that story for our readers? Everybody has a story – unless they’re…
Diabetes affects an estimated 6 million Brazilians, a figure which is expected to double by 2025, in line with many other developing nations. Like many other “rich-country” diseases, there is…
An important topic in Brazil is access to drugs. In recent interviews we have spoken about a third of MS patients being treated, or 10% of hypertensives having their condition…
Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic…
See our Cookie Privacy Policy Here
